|
Re: review of current knowledge of breast cancer brain mets (especially her2+)
Thanks lani,
Very interesting report, which I think is missing the more effective intrathecal trastuzumab. In my opinion when advance BC her2+ patients are taking adjuvent intraveneous trastuzumab they should also take it intrathecally, since the occurrence of brain mets is high. And it seems that nobody is studying this. Amazing.
Mario
|